Autoplaque vs SignalHF

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by APQ Health (formerly Cedars-Sinai Medical Center: AIM)
VS
by Implicity

AI Verdict

Autoplaque is designed for analyzing coronary artery disease from CT images to assess heart attack risk, providing quantitative plaque and stenosis measurements. SignalHF, conversely, leverages data from cardiac implantable electronic devices to predict heart failure hospitalizations, enabling proactive patient management. Therefore, they serve distinct purposes within cardiology, one focusing on anatomical assessment and the other on predictive functional outcomes.

Choose Autoplaque if…

Choose Autoplaque if you require precise, AI-powered quantitative analysis of coronary plaques and luminal stenoses directly from CT angiography images. This tool is ideal for cardiologists and radiologists focused on detailed anatomical assessment for heart attack risk stratification and guiding interventional treatment decisions.

View Autoplaque →

Choose SignalHF if…

Choose SignalHF if you manage patients with cardiac implantable electronic devices and need an AI algorithm to predict heart failure hospitalizations within 30 days. This tool is best suited for care teams aiming to proactively identify high-risk patients, enabling early intervention and personalized care plans to prevent acute heart failure events.

View SignalHF →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Autoplaque SignalHF
Pricing Unknown Contact for pricing
Deployment Workstation-based post-processing application, runs on Windows or Mac OS. SaaS
BAA Available Unknown Yes AI-estimated
FDA Status Cleared AI-estimated Cleared AI-estimated
HIPAA Unknown Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

SignalHF

SignalHF, as a SaaS solution, generally offers superior accessibility and lower IT overhead, contributing to a more streamlined user experience for monitoring and alert management. Autoplaque, being workstation-based, while offering granular control, may require more specific setup and maintenance, potentially impacting broader usability.

Clinical Value

Tie

Both tools are FDA-cleared and address critical needs in cardiology. Autoplaque provides quantitative plaque analysis for heart attack risk prediction, while SignalHF offers predictive AI for heart failure hospitalizations. Both deliver significant, validated clinical value in their respective domains, making it difficult to declare one superior without comparative outcome data.

Pricing & Value

Tie

Both Autoplaque and SignalHF have undisclosed pricing information. Without any details on their cost structures, it is impossible to conduct a meaningful comparison of their pricing or assess their relative value proposition.

Enterprise Readiness

SignalHF

SignalHF explicitly states it is HIPAA compliant and offers a Business Associate Agreement (BAA), which are crucial for enterprise adoption in healthcare. Its SaaS deployment model also provides greater scalability and easier management for large organizations compared to Autoplaque's workstation-based software, which does not specify these compliance details.

Innovation

SignalHF

SignalHF demonstrates higher innovation by leveraging AI to predict heart failure hospitalizations from diverse, manufacturer-agnostic cardiac implantable electronic device data, enabling proactive intervention. This multi-source data integration for predictive risk stratification represents a more advanced and impactful application of AI in clinical workflow compared to automated image segmentation, however sophisticated.

Support & Docs

SignalHF

SignalHF, as a commercial product from Implicity, provides more readily available public documentation such as 'instructions for use' and brochures, along with clear channels for demo requests. While Autoplaque has user manuals, the overall impression is that SignalHF offers a more formalized and accessible support and documentation structure for end-users.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Autoplaque SignalHF
Name Autoplaque SignalHF
Company Cedars-Sinai Medical Center: AIM Implicity
Primary Function AI-powered software for quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, aiding in heart attack risk prediction and treatment guidance. FDA-cleared AI algorithm that predicts heart failure hospitalizations within 30 days by analyzing data from various cardiac implantable electronic devices.
Core Analysis/Prediction AI-powered quantitative analysis of atherosclerotic plaque and measurement of luminal stenoses. Predicts heart failure hospitalizations within 30 days.
Data Source/Input CT Angiographic images Data from various cardiac implantable electronic devices (CIEDs), including physiological data, demographics, lead measurements, episodes, and therapies.

Videos

Demos, reviews, and walkthroughs featuring Autoplaque and SignalHF.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Autoplaque is an AI-powered software for quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, aiding in heart attack risk prediction and treatment guidance. SignalHF is an FDA-cleared AI algorithm that predicts heart failure hospitalizations within 30 days by analyzing data from various cardiac implantable electronic devices, enabling early intervention and personalized care for patients with CIEDs.
Autoplaque performs its AI-powered quantitative analysis using CT angiography images. SignalHF analyzes physiological data, demographics, lead measurements, episodes, and therapies collected from various cardiac implantable electronic devices (CIEDs).
Autoplaque offers AI-powered quantitative analysis of atherosclerotic plaque and luminal stenoses, including automated vessel, plaque, and lumen segmentation that clinicians can review and edit. SignalHF generates automatic alerts for care teams based on predictive risk scores, facilitating early intervention and personalized care plans for heart failure patients.

Backers

Who funded each tool's parent company.

SignalHF

AI Tool Finder
AI-powered search. Results may not be comprehensive.